DX-DRG-B00

DX-DRG-B00 is a preclinical-stage universal antiviral candidate being developed by the South Korean biotechnology company Dx&Vx (formerly known as MG Med) for the treatment of COVID-19. The therapeutic is designed to provide broad-spectrum activity against multiple variants of the SARS-CoV-2 virus, addressing the challenge of viral mutations that can render specific treatments less effective. As of early 2024, the program is in the discovery and preclinical development phase, forming a key part of the company's infectious disease pipeline alongside a universal COVID-19 vaccine candidate.

Brand names

DX-DRG-B00DX-DRG-B-00DX-DRG-B 00

Other names

Universal COVID Anti-viral